Berlin, May 17, 2023 – Bayer announced today that the Chinese National Medical Products Administration (NMPA) granted marketing authorization for a label extension for Kerendia™ (finerenone) to include results on cardiovascular (CV) outcomes from the Phase III FIGARO-DKD study. The study demonstrated that Kerendia reduced the risk of CV events in a broad population of patients with stages 1-4 CKD and T2D…
Read More
